• 2024
  • 2023
  • 2022
  • 2021
  • 2020

R&D Pipeline

R&D Pipeline (In-House)

As of November 2024

Generic Name
/ Development Code
Expected Indications Category Development Stage Development Classification
CG0070 Non-muscle-invasive bladder cancer Oncolytic Viral Therapy Phase III In-licensed /
CG Oncology (U.S.)

Linzagolix
/ KLH-2109

Uterine fibroids GnRH receptor antagonist NDA preparation Kissei
Endometriosis Phase II Kissei
KDT-3594 Parkinson's disease Dopamine receptor agonist Phase II Kissei
KSP-0243 Ulcerative colitis Phase II Kissei


Rovatirelin (spinocerebellar degeneration): Under consideration on the possibility of conducting additional clinical trials



R&D Pipeline (Out-Licensing)

As of November 2024

Generic Name Expected Indications Category Countries & Regions Development Company Development Stage
Linzagolix Uterine fibroids GnRH receptor antagonist Australia Theramex (U.K.) NDA
Taiwan Synmosa Biopharma (Taiwan) NDA
Endometriosis EU Theramex (U.K.) NDA
Fostamatinib Chronic idiopathic thrombocytopenic purpura Tyrosine kinase inhibitor Korea JW Pharmaceutical (Korea) NDA
Silodosin Dysuria associated with benign prostatic hyperplasia Alpha 1A adrenergic receptor antagonist Vietnam, etc. Eisai (Japan) NDA